Clinical Trial

Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma

Name: Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma — clinical trial record (NCT06151106)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.

Protocol Amendment History 2 amendments

This ClinicalTrials.gov record has been amended 2 times since 2023-11-28; most recent amendment 2025-02-18.

Trial Details

NCT Number	NCT06151106
Lead Sponsor	The First Affiliated Hospital of Xiamen University Collaborators: Fujian Cancer Hospital, Zhangzhou Affiliated Hospital of Fujian Medical University, Dongguan People's Hospital, Huizhou Municipal Central Hospital, The First Affiliated Hospital with Nanjing Medical University, Sun Yat-sen University, Shanxi Province Cancer Hospital
Conditions	Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma
Enrollment	33 participants
Start Date	2023-11-22
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-25 (estimated)
Updated on ClinicalTrials.gov	2025-02-19